Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06550128

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Conditions: Hepatitis B, Chronic

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 86
Sponsor: Ausper Biopharma Co., Ltd.

Location: Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou Fujian

Summary

AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.

Eligibility Criteria

Inclusion Criteria: 1. Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study and discontinue their NA therapy according to the protocol; 2. At least 18 years old at the time of signing of the informed consent; 3. Body Mass Index (BMI) between 18 to 32 kg/m\^2(inclusive) ; 4. Participants who are Hepatitis B envelop antigen (HBeAg) negative during screening; 5. Participants whose serum HBsAg positive for at least 6 months prior to screening; 6. Participants who have stable on NA therapy at least 6 months prior to screening; 7. Participants with HBsAg concentration \>100 IU/mL and≤3000 IU/mL, HBV DNA\ 9.0 kPa when screening; 6. Diagnosed or suspected hepatocellular carcinoma; 7. The laboratory examination results are obviously abnormal; 8. History of vasculitis or signs and symptoms of potential vasculitis; 9. History of extrahepatic disease that may be related to HBV immune status; 10. Administration of immunosuppressants within 3 months prior to screening, except for short-term use (≤2 weeks) or topical/inhaled steroids. Administration of immunomodulators (thymosin) and cytotoxic drugs within 6 months prior to the first study intervention or have a history of vaccination within 1 month prior to screening or planned administration during the study. 11. Administration of any Interferon within 6 months prior to screening; 12. History of malignant tumor within the past 5 years; 13. Any suspicion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants; 14. Participants who have significant trauma or major surgery within 3 months before screening, or plan to perform surgery during the study; 15. Blood donation or blood loss more than 400 mL within 12 weeks before screening; Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 month before screening; 16. Concurrently participating in another clinical study, or received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the study treatment or 90 days; 17. Any oligonucleotide or siRNA treatments within 12 months prior to first dosing; 18. Any other circumstances or conditions for which the investigator considers that the participants are inappropriate to participate in the study.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06550128). StuddyBuddy aggregates publicly available trial information.